<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267734</url>
  </required_header>
  <id_info>
    <org_study_id>HOST-ASSURE</org_study_id>
    <nct_id>NCT01267734</nct_id>
  </id_info>
  <brief_title>Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety &amp; EffectiveneSS of Drug-ElUting Stents &amp; Anti-platelet REgimen</brief_title>
  <acronym>HOST-ASSURE</acronym>
  <official_title>Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives&#xD;
&#xD;
        1. To compare the safety and long-term effectiveness of coronary stenting with the new&#xD;
           platform Everolimus-Eluting coronary stenting system (EECSS, Promus Element) compared&#xD;
           with the Zotarolimus-Eluting coronary stenting system (ZECSS, Endeavor Resolute) in&#xD;
           patients with coronary heart disease (CHD)&#xD;
&#xD;
        2. To determine the short-term efficacy and safety of triple anti-platelet therapy (TAT,&#xD;
           Aspirin 100mg qd, Clopidogrel 75mg qd and Cilostazol 100mg bid) compared with&#xD;
           double-dose clopidogrel dual anti-platelet therapy (DDAT, Aspirin 100mg qd and&#xD;
           Clopidogrel 150mg qd) in patients undergoing percutaneous coronary intervention (PCI)&#xD;
           with drug-eluting stents (DES)&#xD;
&#xD;
      Study design Prospective, open-label, 2-by-2 multifactorial, randomized, multicenter trial to&#xD;
      test the following in CHD patients&#xD;
&#xD;
        1. Non-inferiority of Promus Element stent compared with Endeavor Resolute stent in&#xD;
           reducing target lesion failure (TLF)&#xD;
&#xD;
        2. Non-inferiority of TAT compared with DDAT in reducing net clinical outcome Patients will&#xD;
           be randomized in a 2-by-2 factorial manner according to the type of drug eluting stent&#xD;
           (EECSS vs. ZECSS) and the type anti-platelet regimen (TAT vs. DDAT). Randomization will&#xD;
           also be stratified per presence of DM.&#xD;
&#xD;
      Patient enrollment 3750 patients enrolled at 50 centers in Republic of Korea&#xD;
&#xD;
      Patient follow-up Clinical follow-up will occur at 1, 3, 12, 24, 36 months after the&#xD;
      procedure. Angiographical follow-up will be recommended to all participants at 13 months&#xD;
      after the procedure. Investigator or designee may conduct follow-up as telephone contacts or&#xD;
      office visits.&#xD;
&#xD;
      Primary endpoint&#xD;
&#xD;
        1. Target lesion failure (TLF), defined as a composite of cardiac death, target&#xD;
           vessel-related myocardial infarction (MI) and ischemia-driven target lesion&#xD;
           revascularization (TLR) up to 12 months for the stent arm&#xD;
&#xD;
        2. Net clinical outcome, defined as a composite of cardiac death, nonfatal MI, CVA and&#xD;
           major bleeding by PLATO criteria at 1 month for the anti-platelet arm&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary endpoint&#xD;
&#xD;
        1. Clinical and laboratory endpoint at 1 month All death and cardiac death Myocardial&#xD;
           infarction (q wave and non-q wave) Stent thrombosis (definite and possible) CVA&#xD;
           (hemorrhagic and non-hemorrhagic) Bleeding (major and minor) VerifyNow ASA and VerifyNow&#xD;
           P2Y12&#xD;
&#xD;
        2. Clinical endpoint at 12 months All death and cardiac death Target vessel-related MI and&#xD;
           all MI (q wave and non-q wave) Target vessel/lesion revascularization (ischemia-driven&#xD;
           and all) Stent thrombosis (definite/possible/probable) Net clinical outcome including&#xD;
           bleeding (major and minor) Acute success of procedure (device, lesion and procedure)&#xD;
&#xD;
        3. Angiographic (including IVUS or OCT) endpoint at 13 months In-stent &amp; In-segment late&#xD;
           loss In-stent &amp; In-segment % diameter stenosis Angiographic pattern of restenosis&#xD;
           Neointimal volume, % neointimal volume and % volume obstruction on IVUS or OCT Degree of&#xD;
           stent strut endothelialization on OCT&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of cardiac death, target vessel-related myocardial infarction (MI) and ischemia-driven target lesion revascularization (TLR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Net clinical outcome</measure>
    <time_frame>1 month</time_frame>
    <description>Composite of cardiac death, nonfatal MI, CVA and major bleeding by PLATO criteria</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3750</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>EECSS + DDAT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Promus Element stent + double-dose clopidogrel anti-platelet therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZECSS + DDAT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endeavor Resolute stent + double-dose clopidogrel anti-platelet therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EECSS + TAT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Promus Element stent + triple anti-platelet therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZECSS + TAT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endeavor Resolute stent + triple anti-platele therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting coronary stenting system (EECSS, Promus Element)</intervention_name>
    <description>Everolimus-eluting stent</description>
    <arm_group_label>EECSS + DDAT</arm_group_label>
    <arm_group_label>EECSS + TAT</arm_group_label>
    <other_name>Promus Element</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)</intervention_name>
    <description>Zotarolimus-eluting stent</description>
    <arm_group_label>ZECSS + DDAT</arm_group_label>
    <arm_group_label>ZECSS + TAT</arm_group_label>
    <other_name>Endeavor Resolute</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple anti-platelet therapy (TAT)</intervention_name>
    <description>100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month</description>
    <arm_group_label>EECSS + TAT</arm_group_label>
    <arm_group_label>ZECSS + TAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double-dose clopidogrel anti-platelet therapy (DDAT)</intervention_name>
    <description>100mg Aspirin QD + 150mg Clopidogrel QD for 1 month</description>
    <arm_group_label>EECSS + DDAT</arm_group_label>
    <arm_group_label>ZECSS + DDAT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria&#xD;
&#xD;
          -  Subject must be at least 18 years of age.&#xD;
&#xD;
          -  Subject is able to verbally confirm understandings of risks, benefits and treatment&#xD;
             alternatives of receiving the Promus Element or Endeavor Resolute stents, and he/she&#xD;
             or his/her legally authorized representative provides written informed consent prior&#xD;
             to any study related procedure.&#xD;
&#xD;
          -  Subject must have significant lesion (&gt;50% by visual estimate) in any of the coronary&#xD;
             arteries, venous or arterial bypass grafts.&#xD;
&#xD;
          -  Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina,&#xD;
             recent infarction, silent ischemia, positive functional study or a reversible changes&#xD;
             in the electrocardiogram (ECG) consistent with ischemia). In subjects with diameter&#xD;
             stenosis &gt; 70%, evidence of myocardial ischemia does not have to be documented.&#xD;
&#xD;
        Angiographic Inclusion Criteria&#xD;
&#xD;
          -  Target lesion(s) must be located in coronary artery, venous or arterial bypass graft&#xD;
             with diameter of ≥ 2.5 mm and ≤ 4.00 mm.&#xD;
&#xD;
          -  Target lesion(s) must be amenable for percutaneous coronary intervention.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  The patient has a known hypersensitivity or contraindication to any of the following&#xD;
             medications: Heparin, Aspirin, Clopidogrel, Cilostazol, Everolimus, Zotarolimus,&#xD;
             Contrast media (Patients with documented sensitivity to contrast media which can be&#xD;
             effectively premedicated with steroids and diphenhydramine [e.g. rash] may be&#xD;
             enrolled. Those with true anaphylaxis to prior contrast media, however, should not be&#xD;
             enrolled.)&#xD;
&#xD;
          -  Systemic (intravenous) Everolimus or Zotarolimus use within 12 months.&#xD;
&#xD;
          -  Female of childbearing potential, unless a recent pregnancy test is negative, who&#xD;
             possibly plan to become pregnant any time after enrollment into this study.&#xD;
&#xD;
          -  History of bleeding diathesis, known coagulopathy (including heparin-induced&#xD;
             thrombocytopenia), abnormal hemogram (Hb&lt;10g/dL or PLT count &lt;100,000/μL) or will&#xD;
             refuse blood transfusions&#xD;
&#xD;
          -  Patients with severe LV systolic dysfunction (LVEF&lt;25%) or cardiogenic shock&#xD;
&#xD;
          -  Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery&#xD;
             within 2 months.&#xD;
&#xD;
          -  Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that may&#xD;
             result in protocol non-compliance (per site investigator's medical judgment).&#xD;
&#xD;
          -  Patients who are actively participating in another drug or device investigational&#xD;
             study, which have not completed the primary endpoint follow-up period.&#xD;
&#xD;
          -  Symptomatic heart failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung Woo Park, MD, PhD</last_name>
    <phone>82-2-2072-0244</phone>
    <email>kwparkmd@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyo-Soo Kim, MD, PhD</last_name>
    <phone>82-2-2072-2226</phone>
    <email>hyosoo@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung Woo Park, MD, PhD</last_name>
      <phone>82-2-2072-0244</phone>
      <email>kwparkmd@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Hyo-Soo Kim, MD, PhD</last_name>
      <phone>82-2-2072-2226</phone>
      <email>hyosoo@snu.ac.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>December 27, 2010</study_first_submitted>
  <study_first_submitted_qc>December 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2010</study_first_posted>
  <last_update_submitted>December 15, 2013</last_update_submitted>
  <last_update_submitted_qc>December 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <name_title>Hyo-Soo Kim</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>Everolimus</keyword>
  <keyword>Zotarolimus</keyword>
  <keyword>Cilostazol</keyword>
  <keyword>Clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

